Radiopharmaceuticals for Relapsed or Refractory Leukemias

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Mar 13

PMID 30859091

Citations 3

Authors

Charles A Kunos

Jacek Capala

Susan Percy Ivy

Affiliations

Soon will be listed here.

Abstract

Radiopharmaceuticals, meaning drugs that hold a radionuclide intended for use in cancer patients for treatment of their disease or for palliation of their disease-related symptoms, have gained new interest for clinical development in adult patients with relapsed or refractory leukemia. About one-third of adult patients outlive their leukemia, with the remainder unable to attain complete remission status following the first phase of treatment due to refractory bone marrow or blood residual microscopic disease. The National Cancer Institute (NCI) Cancer Therapy Evaluation Program conducted 49 phase 1-1b trials in adult patients with leukemia between 1986 and 2017 in an effort to discover tolerated and effective therapeutic drug combinations intended to improve remission and mortality rates. None of these trials involved radiopharmaceuticals. In this article, the NCI perspective on the challenges encountered in and on the future potential of radiopharmaceuticals alone or in combination for adult patients with relapsed or refractory leukemia is discussed. An effort is underway already to build-up the NCI's clinical trial enterprise infrastructure for radiopharmaceutical clinical development.

Citing Articles

Radiopharmaceutical Chemistry and Drug Development-What's Changed?.

Kunos C, Mankoff D, Schultz M, Graves S, Pryma D Semin Radiat Oncol. 2020; 31(1):3-11.

PMID: 33246634 PMC: 7703672. DOI: 10.1016/j.semradonc.2020.07.006.

Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats.

Williams B, Law A, Hunyadkurti J, Desilets S, Leyton J, Keating A J Clin Med. 2019; 8(8).

PMID: 31434267 PMC: 6723634. DOI: 10.3390/jcm8081261.

Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer.

Kunos C, Capala J, Kohn E, Ivy S Front Oncol. 2019; 9:560.

PMID: 31297338 PMC: 6607970. DOI: 10.3389/fonc.2019.00560.

References

Finch R, Liu M, Cory A, CORY J, Sartorelli A . Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul. 1999; 39:3-12. DOI: 10.1016/s0065-2571(98)00017-x. View

Finch R, Liu M, Grill S, Rose W, LOOMIS R, Vasquez K . Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol. 2000; 59(8):983-91. DOI: 10.1016/s0006-2952(99)00419-0. View

Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K . Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000; 14(8):1436-43. DOI: 10.1038/sj.leu.2401851. View

Feldman E, Kalaycio M, Weiner G, Frankel S, SCHULMAN P, Schwartzberg L . Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia. 2003; 17(2):314-8. DOI: 10.1038/sj.leu.2402803. View

Giles F, Fracasso P, Kantarjian H, Cortes J, Brown R, Verstovsek S . Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003; 27(12):1077-83. DOI: 10.1016/s0145-2126(03)00118-8. View

Caron P, Co M, Bull M, Avdalovic N, Queen C, Scheinberg D . Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res. 1992; 52(24):6761-7. View

Tallman M, Gilliland D, Rowe J . Drug therapy for acute myeloid leukemia. Blood. 2005; 106(4):1154-63. DOI: 10.1182/blood-2005-01-0178. View

Hubeek I, Peters G, Broekhuizen A, Talianidis I, Sigmond J, Gibson B . Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. J Clin Pathol. 2005; 58(7):695-9. PMC: 1770710. DOI: 10.1136/jcp.2004.023861. View

Hakansson P, Hofer A, Thelander L . Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem. 2006; 281(12):7834-41. DOI: 10.1074/jbc.M512894200. View

10.

Gojo I, Tidwell M, Greer J, Takebe N, Seiter K, Pochron M . Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res. 2007; 31(9):1165-73. DOI: 10.1016/j.leukres.2007.01.004. View

11.

Karp J, Giles F, Gojo I, Morris L, Greer J, Johnson B . A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive.... Leuk Res. 2007; 32(1):71-7. PMC: 2726775. DOI: 10.1016/j.leukres.2007.05.003. View

12.

Odenike O, Larson R, Gajria D, Dolan M, Delaney S, Karrison T . Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008; 26(3):233-9. PMC: 4283497. DOI: 10.1007/s10637-008-9115-6. View

13.

Pitceathly R, Fassone E, Taanman J, Sadowski M, Fratter C, Mudanohwo E . Kearns-Sayre syndrome caused by defective R1/p53R2 assembly. J Med Genet. 2011; 48(9):610-7. DOI: 10.1136/jmg.2010.088328. View

14.

Ganzel C, Becker J, Mintz P, Lazarus H, Rowe J . Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev. 2012; 26(3):117-22. DOI: 10.1016/j.blre.2012.01.003. View

15.

Sekeres M, Lancet J, Wood B, Grove L, Sandalic L, Sievers E . Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2012; 98(1):119-28. PMC: 3533673. DOI: 10.3324/haematol.2012.066613. View

16.

Petersdorf S, Kopecky K, Slovak M, Willman C, Nevill T, Brandwein J . A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013; 121(24):4854-60. PMC: 3682338. DOI: 10.1182/blood-2013-01-466706. View

17.

Sandoval M, Balakrishnan K, Luthra R, Keating M, Gandhi V . DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells. Leuk Lymphoma. 2013; 55(4):876-83. PMC: 4102412. DOI: 10.3109/10428194.2013.813497. View

18.

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

19.

Chittenden S, Hindorf C, Parker C, Lewington V, Pratt B, Johnson B . A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases. J Nucl Med. 2015; 56(9):1304-9. DOI: 10.2967/jnumed.115.157123. View

20.

Eichhorst B, Cramer P, Hallek M . Initial therapy of chronic lymphocytic leukemia. Semin Oncol. 2016; 43(2):241-50. DOI: 10.1053/j.seminoncol.2016.02.005. View